
Codexis
Founded Year
2002Stage
PIPE | IPOTotal Raised
$92MMarket Cap
0.11BStock Price
1.56About Codexis
Codexis discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Expert Collections containing Codexis
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Codexis is included in 3 Expert Collections, including Synthetic Biology.
Synthetic Biology
305 items
Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.
Advanced Materials
1,313 items
Companies in the advanced materials space, including polymers, biomaterials, semiconductor materials, and more
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Codexis Patents
Codexis has filed 521 patents.
The 3 most popular patent topics include:
- Molecular biology
- RNA
- Virus families

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
7/17/2019 | 9/19/2023 | Virus families, Sugar substitutes, Molecular biology, RNA, Virology | Grant |
Application Date | 7/17/2019 |
---|---|
Grant Date | 9/19/2023 |
Title | |
Related Topics | Virus families, Sugar substitutes, Molecular biology, RNA, Virology |
Status | Grant |
Latest Codexis News
Sep 18, 2023
Redwood City, California, UNITED STATES REDWOOD CITY, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, has been named a finalist for the prestigious 2023 Bloom Burton Award. Bestowed annually and nominated by the public at large, the Bloom Burton Award honors an individual who made the greatest contribution to Canada’s innovative healthcare industry the previous year. Dr. Dilly has been recognized for his leadership of Vancouver-headquartered Sierra Oncology, where he led the company through the Phase 3 clinical development of momelotinib and its drive toward commercialization as well as the company’s $1.9 billion acquisition by GSK. “It is an honor to be named as a finalist for the 2023 Bloom Burton Award. Leading the team at Sierra Oncology to bring momelotinib to the patients who would most benefit was an energizing experience and a highlight of my career. GSK recognized the value of the compound the same way we did and joined forces with us to help accelerate delivery to patients on a global scale,” said Dr. Dilly. “I am incredibly grateful to the physicians and patients who participated in our clinical trials, and the entire team at Sierra who worked diligently to meet demanding timelines throughout the development process. This nomination is a recognition of the work of the entire team and our collective vision to transform promise into patient impact.” The Bloom Burton Award finalists and winner are chosen by an independent panel of judges consisting of international leaders in healthcare investment, entrepreneurship and journalism. The winner will be announced live at the Bloom Burton Award Gala on September 28, 2023, at the Four Seasons Hotel Toronto. For more information, please visit www.bloomburton.com/gala . About Codexis Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis, and the Company is currently developing its proprietary ECO Synthesis™ platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com . For More Information
Codexis Frequently Asked Questions (FAQ)
When was Codexis founded?
Codexis was founded in 2002.
Where is Codexis's headquarters?
Codexis's headquarters is located at 200 Penobscot Drive, Redwood City.
What is Codexis's latest funding round?
Codexis's latest funding round is PIPE.
How much did Codexis raise?
Codexis raised a total of $92M.
Who are the investors of Codexis?
Investors of Codexis include Casdin Capital, Shell, Chevron Technology Ventures, Presidio Partners, Pequot Venture Capital and 5 more.
Who are Codexis's competitors?
Competitors of Codexis include Allozymes, Viridos, Erbi Biosystems, Cradle, Enerkem and 14 more.
Compare Codexis to Competitors

Viridos develops and commercializes genomic-driven solutions to address global energy and environmental challenges. It builds a platform for low-carbon-intensity biofuels that can reduce greenhouse gas emissions from aviation, commercial trucking, and maritime shipping. The company was formerly known as Synthetic Genomics. It was founded in 2005 and is based in La Jolla, California.
Cellencor Corporation is a new company whose aims to reshape the economics of the global renewable energy industry. Transformative technology will be offered to ethanol and other cellulosic energy providers

Praj Industries Limited is a Biofuels Technology Company with a number of processes and systems for ethanol and biodiesel production to its credit.

Endel provides a personalized sound environment platform. Its algorithm is based on circadian rhythms, pentatonic scale, and sound masking. The sounds adapt to different inputs, like time of day, weather, heart rate, and location, boosting a user's productivity and cognitive abilities. It was founded in 2018 and is based in Berlin, Germany.
Greenline Industries manufactures biodiesel production equipment.
NextDiesel biodiesel and Biofuel Industries Group are producers of high grade B100 biodiesel fuel